博騰股份(300363.SZ):擬不超過5000萬元參與認購投資基金份額
格隆匯2月26日丨博騰股份(300363.SZ)公佈,公司擬以自有資金認繳出資不超過5,000萬元人民幣參與投資由深圳市松禾資本管理有限公司(簡稱“松禾資本”)管理的深圳市松禾細胞與基因產業私募股權投資基金(有限合夥)(簡稱“基金”或“本合夥企業”),作為有限合夥人,基金規模15億人民幣。基金100%圍繞細胞與基因領域進行投資佈局,包括細胞和基因治療、新型病毒載體、新型疫苗研發及產業化、基因技術、生物育種研發及產業化和上述領域所需的上游產業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.